Peptides targeting Toll-like receptor (TLR) signaling pathways offer new immune therapeutic opportunities — both TLR agonist peptides for immune activation and antagonist peptides for anti-inflammatory applications.
Key findingPeptides targeting Toll-like receptor (TLR) signaling pathways offer new immune therapeutic opportunities — both TLR agonist peptides for immune activ
What the researchers found
Peptides targeting Toll-like receptor (TLR) signaling pathways offer new immune therapeutic opportunities — both TLR agonist peptides for immune activation and antagonist peptides for anti-inflammatory applications.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
Current pharmaceutical design, 16(9), 1063-80
Citation
Gomariz, R P; Gutiérrez-Cañas, I; Arranz, A; Carrión, M; Juarranz, Y; Leceta, J; Martínez, C. (2010). Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.. Current pharmaceutical design, 16(9), 1063-80.